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Objective(s): Extracellular matrix (ECM) is composed of many kinds of glycoproteins containing 
glycosaminoglycans (GAGs) moiety. The research was conducted based on the N-Acetylgalactosamine 
(GalNAc) degradation of ECM components by α-N-acetylgalactosaminidase (Nagalase) which facilitates 
migration and invasion of cancer cells. This study aims to investigate the effects of Naga-shRNA 
downregulation on migration and invasion of cancer cell lines. 
Materials and Methods: In this study, MCF-7 cell line (human mammary carcinoma cell line) and A2780 
(human ovarian carcinoma cell line) were used. The level of normalized Naga expression and Nagalase 
protein were evaluated by quantitative polymerase chain reaction and enzyme-linked immunosorbent 
assay/western blotting, respectively. Migration and invasion were determined using transwell assays, 
and statistical analysis was carried out by ANOVA test.  
Results: Response to transduction by shRNA compared to the control group, migrative and invasive 
properties of the transfected cells were significantly inhibited. 
Conclusion: These results indicate that Nagalase may have an important role in migration and invasion 
of cancer cells and can be considered as a candidate for further studies. 
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Introduction 
Cancer has been known as the cause of more than 
8 million deaths annually around the world (1). 
Various treatment strategies have been used so far, 
however, none of them is a certain therapy for cancer 
treatment. Therefore, cancer diagnosis in early stages 
or in the pre-metastatic stage can greatly affect the 
treatment process (2, 3). In this regard, several tumor 
markers have been proposed, and their efficiency            
has been evaluated. α-N-AcetylGalactosaminidase 
(Nagalase) serum level elevation has been observed 
in cancer patients in many studies particularly in 
primary and metastatic stages (4-6). Although much 
evidence confirm elevated levels of Nagalase in serum 
of breast, colon, and prostate cancers, other studies 
endorse this subject in gastrointestinal system cancer, 
genital system, neural system, respiratory system  
and various leukemias (7-9). Nagalase (E.C. 3.2.1.49) 
cleaves α-N-Acetylgalactosaminyl moieties from 
Thr/Ser in glycoprotein O-linkage. This enzyme was 
detected not only in humans, but in all eukaryotes            
and prokaryotes even in viruses. Nagalase deficiency  
causes a rare hereditary lysosomal storage disease 
named Schindler/Kanzaki, a heterogeneous genetic 
disorder which is known more as a metabolic disease 
(10). Nagalase deficiency has a wide spectrum of 
clinical symptoms. neuroaxonal dystrophy in an early 
stage is called Schindler disease and angiokeratoma 
corporis diffusum in late stage is called Kanzaki 
disease (11, 12). 
Although researchers are not sure about the role of 
various factors in cancer metastasis, it can be assumed 
that altered glycosylations play an important role in the 
occurrence of metastasis cascade (13). There is some 
evidence that suggests Nagalase acts as an extracellular 
matrix-degrading enzyme (14, 15). It seems degradation 
of glycoproteins/ proteoglycans containing GalNAc side 
chains have an important role in this process, because of 
its considerable amount in extracellular matrix (ECM). 
ECM composition and the structure of ECM components 
in cancerous tissues and the correlation of ECM with 
macrophage activity and chemotaxis to target tissue are 
not understood completely. Evidence also shows changes 
in the GalNAc components of the extracellular matrix 
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and extracellular membrane attachment component 
such as integrins in cancer tissues or cells (16, 17). These 
findings confirm that the presence of Nagalase in many 
pathogens such as bacteria, parasites and viruses may be 
effective in their spreading in the body (15, 18, 19). One 
of the most important role of Nagalase has been 
investigated in macrophage suppression (20). 
Macrophages play an indispensable role in recovery 
process of most diseases. Several mechanisms are 
involved in the activation of macrophages which are 
not exactly identified. Vitamin D binding protein=DBP 
(and known as group specific component=Gc) is 
derived by the activation of β-galactosidase and 
sialidase membrane-bound enzymes which activate B 
cell and T cell lymphocytes, respectively, is called 
DBP-macrophage activating factor (DBP-MAF) or Gc-
MAF (21). Gc-MAF is administered as a therapeutic 
agent in cancer immunotherapy and many evidence 
support its high efficacy in cancer patients or cell lines 
(6, 22, 23). Deglycosilation of DBP by Nagalase 
secreted by cancer cells inhibits the production of 
MAF (8, 20). In cell lines, the same results were seen 
after addition of Gc-MAF (24-26). Altogether, there are 
several evidence indicating that serum level of Nagalase 
have a significant relationship with tumor burden 
(regardless of its type), in that parallel to tumor size 
shrinkage, the level of Nagalase in serum decreases. (27). 
That is why some investigators proposed Nagalase as a 
diagnostic and prognostic marker of cancer (5, 6, 27). 
Based on the evidence mentioned above, in this study 
the role of Nagalase in migration and invasion of MCF-7 
(breast cancer cell line) and A2780 (ovarian cancer cell 
line) was investigated. 
 
Materials and Methods 
Cell culture 
Human breast cancer cell line (MCF7) and human 
ovarian cancer cell line (A2780) were obtained  from 
BuAli Research Center (Mashhad University of Medical 
Sciences, Mashhad, Iran). All cells were cultured in 
RPMI1640 medium (Caisson, USA) with 10 % (v/v) fetal 
bovine serum-FBS (Gibco, USA), streptomycin (100 
µg/ml) and penicillin (100 U/ml) (CMG, Iran). The cells 
were incubated at 37 °C in a humidified atmosphere and 
5% CO2. The cells were sub-cultured when reached the 
confluency of 80-90% using 0.25% Trypsin-EDTA 
(Gibco, USA). 
 
Vector construction and transfection 
All cells were transfected with Naga shRNA 
plasmid (h) including 3 target-specific lentiviral vector 
plasmids each encoding 19-25 nt (plus hairpin) shRNAs 
(sc-75860-SH, SantaCruz Biotechnology) to knock-
down Naga gene expression. In order to neutralize the 
external interfering factors the control shRNA plasmid-
A, encoding a scrambled shRNA sequence that will not 
lead to the specific degradation of any known cellular 
mRNA (sc-108060, SantaCruz Biotechnology), and 
copGFP control plasmid which contains the full-length 
copGFP gene-natural green monomeric GFP-like protein 
from copepod (Pontellina sp.) with optimized human 
codons for high level expression of the fluore-scent 
protein from the CMV promoter in mammalian cells, (sc-
108083, SantaCruz Biotechnology) were used. The 
sequences in the shRNA expression cassettes were 
verified to correspond to the target gene with 100% 
identity. The sequences of shRNAs are listed in Table 1.  
Cell viability was assessed by trypan blue staining before 
transfection. Transfection was performed according to 
the manufacturer’s instructions. After transfection, cells 
stably expressing shRNAs were isolated using 
puromycin selection. 
Briefly, cells were seeded in a 24-well plate at a 
density of 1×105 cells/well in 500 µl antibiotic-free 
normal growth medium supplemented with 10% FBS  
24 hr before the transfection. For each well, 2.5 μl (250 
ng) of the shRNA were mixed with 22.5 μl transfection 
medium (sc-108062, SantaCruz Biotechnology) and 
incubated at room temperature for 45 min with                  
1.5 µl transfection reagent (sc-108061, SantaCruz 
Biotechnology) and 23.5 μl transfection medium. After 
washing the cells transfection medium, 50 μl of 
transfection mixtures were added to each well with 200 
μl transfection medium. 6-8 hr after transfection,  
the medium was replaced with fresh RPMI medium 
containing 20% FBS. After 18-24 hr medium was 
changed using RPMI containing 10% FBS and 3 µg/ml 
puromycin (sc-108071, SantaCruz Biotechnology) for 
antibiotic selection. The cells were incubated at 37 °C 
with 5% CO2. Transfection efficiency was assessed by 
the expression of green fluorescent protein (GFP) 
under a florescence microscope (Figure 1A). After 24 
hr, live transfected cells were used for RNA or protein 
isolation as well as migration/invasion assay. To  
perform further examinations (qPCR, ELISA,  Western
Table 1. Three different shRNA plasmids of Naga shRNA plasmid, corresponding small interfering RNA (siRNA) sequences 
 
Hairpin sequence (5′ → 3′) siRNA sequences (5′ → 3′) 
GATCCCGAGATGAAACCAACTTCATTCAAGAGATGAAGTTGGTTT
CATCTCGTTTTT 
Sense: CGAGAUGAAACCAACUUCAtt 
Antisense: UGAAGUUGGUUUCAUCUCGtt 
GATCCCCTTGCTGTTGACTCTGAATTCAAGAGATTCAGAGTCAAC
AGCAAGGTTTTT 
Sense: CCUUGCUGUUGACUCUGAAtt 
Antisense: UUCAGAGUCAACAGCAAGGtt 
GATCCGGACATTTATTCCCTTCTATTCAAGAGATAGAAGGGAATA
AATGTCCTTTTT 
Sense: GGACAUUUAUUCCCUUCUAtt 
Antisense: UAGAAGGGAAUAAAUGUCCtt 
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blot, migration and invasion) each cell line was 
transfected in 12 wells. To obtain statistically reliable 
results, experiments were performed in triplicate. 
Control wells transfected by scrambled plasmid were 
used during all steps mentioned above, and their 
culture medium was exchanged along with tests. 
 
Puromycin screening 
To eliminate the un-transfected cells within the 
cell population, the transfected cells were treated 
with different doses of puromycin. The minimum 
lethal dose of puromycin to mortify un-treated cells in 
24 hr was determined after microscopic screening. 
The results indicate that un-transfected cells will die 
at 3 μg/ml puromycin concentration. Therefore, after 
plasmid transfection and selection by puromycin 
treatment, (un-transfected cells) wells were washed 
gently to eliminate dead cells, and adherent living 
cells were used for further studies (Figure 1B). 
 
(A) 
 
  
(B)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. (A) The MCF7 cells in the Naga-shRNA group demons-
trate green ﬂuorescence under the exciting wavelength.                        
The transfection efficiency was ≥50% for the other two transfection 
groups. (B) Cell death mediated by 3 μg/ml puromycin concentration 
(400X) 
 
 
Quantitative RT-PCR analysis (RT-qPCR) 
RNA was extracted by Total RNA extraction Kit-
A101231 (ParsTous, Iran) according to the manufac-
turer’s protocol. Then, RNA concentration was 
measured (NanoDrop One/Onec, Thermo Fisher 
Scientific Inc., US) and cDNA was synthesized by 
PrimeScript™ 1st strand cDNA Synthesis Kit-6110B 
(Takara Bio Inc., Japan) according to the manufac-
turer’s instructions. The primers designed for Naga 
expression analysis were as follows: forward                      
5′-ACGCTTCCGCTGCAACATTAACTG-3′ and reverse 
5′-CCACCGATCCAGCAGTCATCAATG-3′. Naga gene 
expression was normalized to β-Actin as internal 
control. The primer sequences for β-Actin were as 
follows: F5′-TCATGAAGTGTGACGTGGACATC-3′ and 
reverse 5′-CAGGAGGAGCAATGATCTTGATCT-3′ (Macrogen 
Inc., Korea) (28). The primer was synthesized based 
on sequences mentioned above and quantitative RT-
PCR analysis was performed using RealQ Plus 2X 
MasterMix Green-without RoxTM (A323402, Amplicon, 
Denmark) in a Rotor-Gene Q 96-RT-PCR instrument 
(QiaGen Inc., Germany). Briefly, first-strand cDNA was 
reverse transcribed from 1 µg total RNA using MMLV 
reverse transcriptase (Takara, Japan). For each qPCR 
reaction, a master mix was prepared containing 
SyberGreen MasterMix, forward and reverse primers 
(5 pµ), and 10-50 ng template cDNA. The PCR cycling 
conditions were 5 min at 95 °C followed by 35 cycles 
of 95 °C for 10 sec, 64 °C for 10 sec, and 72 °C for                     
15 sec. Melt curve analysis confirmed specific 
amplification. The PCR products were kept at 4 °C. All 
RT-qPCR reactions were performed in triplicate. To 
evaluate the impact of transfection, the relative 
expression of Naga mRNA was calculated using ΔΔCT 
the method of comparative threshold cycle (Cp) with 
the following formula: (2-ΔΔCp=2-ΔCp (target gene)-ΔCp (bActin)) 
 
Enzyme linked immunosorbent assay (ELISA) 
In order to ensure the effectiveness of transfection, 
cell lysate was prepared by sonication (Hielscher-
Ultrasound Technology, Germany), 10 cycles (5 sec on/5 
sec off) by 70% amplitude on ice. Lysate was centrifuged 
in 10.000 g at 4 °C, and the supernatant was separated. 
α-N-acetylgalactosaminidase commercial ELISA kit 
were used (Cloud-Clone Corporation, China), and the 
assay was performed according to the manufacturer’s 
instructions (detection range; 0.3-20 ng/ml). 
 
Western blotting (WB) 
Total protein was extracted as described above              
and protein concentrations were determined. Cell 
lysates (20–30 mg) were separated in a 10% sodium 
dodecyl sulfate–polyacrylamide gel electrophoresis 
(SDS-PAGE), and then transferred to nitrocellulose 
membranes. The membranes were blocked in 5% 
skimmed milk at 37˚C for 1 hr. The membranes were 
incubated with mouse anti-human Naga (dilution 
1:200; 47kD; sc-393485, SantaCruz Biotechnology, 
US) and β-actin as internal control (dilution 1:1000; ~43 
kD; sc-47778, SantaCruz Biotechnology, US) antibodies 
at 4˚C overnight. The membranes were then washed and 
incubated with the goat anti-mouse IgG antibody 
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conjugated with horseradish peroxidase (dilution 
1:1000, sc-2005, SantaCruz Biotechnology, US) as 
secondary antibody with shaking for 2 hr at room 
temperature. The intensity of protein bands was 
detected using chemiluminescence-substrate detection 
kit (B111420, ParsTous, Iran) according to the manu-
facturer's instructions. Results were scanned and 
analyzed using GelQuant.NET software provided by 
‘biochemlabsolutions.com’.  
 
Transwell migration assay 
Cell migration analyses were performed in 24-well 
8 μm pore size polycarbonate transwell plates (SPL, 
Korea) according to the manufacturer’s instructions. 
After 48 hr post-transfection, puromycin-selected 
cells in each group were cultured using low serum 
medium (5% FBS) and washed gently to remove non 
transfected cells (not for un-treated group). The 
bottom chamber was filled with culture medium 
containing 20% FBS. Cells (transfected with Naga-
plasmid, scramble plasmid and untreated control) 
were trypsinized and suspended at a density of 5×104 
cells/ml in serum-free medium, and 100 μl of cell 
suspension was plated in the upper chamber. The 
cells were wiped out gently from the upper surface of 
the chamber using a cotton swab after 24 hr 
incubation with 5% CO2 at 37 °C. The cells that 
migrated to the lower surface of the membrane were 
washed with PBS, fixed in formaldehyde 3.7% for 2 
min and methanol for 15 min. The cells were then 
stained with 0.1 % Giemsa for 10 min, and rinsed with 
distilled water several times. The cells were counted 
on the lower surface of the filters in 5 random 
microscopic fields using an FSX100 light microscope 
(Olympus, Japan) at 400X magnification.  
For invasion assay, the transwell 24-well insert 
plate was precoated with 100 µl of matrigel ECM-gel 
(Sigma, US) diluted 1:4 with serum-free RPMI 
medium at 37 ºC overnight. 5×104 cells of three 
groups were seeded onto the insert as described for 
migration assay and then incubated for 24 hr in 37ºC. 
The cells that invaded the lower surface of the 
membrane were stained and counted as described 
above. Cell viability assay was used (trypan blue vital 
stain) before use in migration and invasion assay. 
 
Statistical analysis 
Independent experiments were performed in 
triplicate on each cell line in independent cultures. All 
data were analyzed using ANOVA test by statistical 
software GraphPad Prism-6 and expressed as mean ± 
standard error of the mean (SEM). The significance 
level was set at P-value<0.05.  
 
Results  
Naga-shRNA decreases the expression of nagalase 
In the present study, a copGFP vector was used to 
silence Naga gene with shRNA. After transfection, based 
on ratio of fluorescence-positive cells, transfection 
efficiency was estimated to be more than 50% (Figure 
1A). RT-qPCR was performed to evaluate the changes in 
mRNA expression. Based on melting curve analysis,                 
all tests showed a single peak of the desired amplicons,             
and negative control group showed no peak, which 
confirms the results. RT-qPCR analysis revealed 
significant decrease of Naga-mRNA expression in Naga-
shRNA groups (NG) compared to the negative control 
group (NC) and Scramble-shRNA group (SC) in both                 
cell lines (all tests were performed in triplicates)                     
(P<0.05). Despite this difference between the cell lines, 
MCF-7 cells transduced with Naga-shRNA had the 
lowest Naga-mRNA expression compared to the other 
two control groups (NC & SC) (P-value<0.05). While no 
significant difference of Naga-mRNA expression was 
observed between negative control group (NC) and 
scramble-shRNA group (SC), a little difference was 
detected in both cell lines (Figure 2). 
 
Analysis of nagalase protein expression 
Based on ELISA assay, in both cell lines nagalase 
expression in Naga-shRNA group, compared to negative 
control group (NC) and Scramble-shRNA group (SC), 
was significantly decreased (P<0.05), but no significant 
difference was observed between Negative control 
group (NC) and Scramble-shRNA group (SC)(P>0.05).  
 
 
 
  
 
 
Figure 2. The relative Naga mRNA expression in cell lines following 
transfection with shRNA plasmid. The expression of mRNA was 
measured with reverse transcription quantitative polymerase 
chain reaction (RT-qPCR). Naga mRNA expression was significantly 
suppressed by shRNA vector compared to scramble-plasmid 
controls. Naga group (cells transfected with Naga-plasmid); 
Scramble group (cells transfected with scramble plasmid). Data are 
shown as mean±SEM of triplicate experiments in compare to 
control group (un-treated cells) and β-actin was included as an 
internal control. ** P-value <0.01  
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Figure 3. The nagalase protein expression in cell lines following 
transfection with shRNA plasmid was examined by enzyme linked 
immunosorbent assay. Nagalase protein expression was significantly 
decreased by shRNA plasmid compared to controls. Control group (un-
transfected cells); Naga group (cells transfected with Naga-plasmid); 
plasmid group (cells transfected with scramble pasmid). Data are 
shown as mean ± SEM of triplicate experiments. ** P<0.01 
 
 
The results demonstrated the expression levels 
of Nagalase protein in the MCF7 and A2780 cells were 
significantly decreased, 72 hr following transfection, 
which confirms the downregulation of the gene (Figure 
3). Also nagalase and β-Actin (as internal control) 
expression was detected in these cells by Western 
blotting. As shown in Figure 4, Western blot analysis also 
showed a significant decrease in nagalase expression in 
both transfected cell lines compared to negative control 
group (NC) and scramble-shRNA group (SC).  
 
Effect of naga silencing on cell migration and invasion 
In our study, transwell assay and Matrigel transwell  
 
 
 
Figure 4. The relative nagalase protein expression assay by Western 
blot. Nagalase protein expression was significantly decreased by shRNA 
plasmid compared to controls. The average signal intensity was 
normalized by internal control. Naga group (cells transfected with 
Naga-plasmid); scramble group (cells transfected with scramble 
plasmid). Data are shown as mean ± SEM of triplicate experiments in 
compare to control group (un-treated cells) and β-actin was included as 
an internal control. ** P<0.01 
 
 
 
assay were used to evaluate migration and metastatic 
potential of cancer cells, respectively. Results showed 
lower migration and invasion capacities after Naga-
shRNA treatment compared to both control groups (un-
treated group and scramble shRNA group) in both cell 
lines, and these differences were significant in both MCF7 
and A2780 (P-value<0.05). Regarding the number                          
of migrated/metastasized cancer cells, no significant 
difference was observed between scramble-shRNA group 
and un-treated group in both cell lines (P-value>0.05) 
(Figure 5). 
 
        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Cell migration and invasion evaluation by transwell assay. The comparison of the average amount of migrated/invaded cells of the 
groups. The cells penetrating the filter membrane were stained with geimsa and distinguished under a light microscope 400X. (A, B) 
migration and (C, D) invasion ability was significantly decreased by shRNA vector compared to controls in MCF7 & A2780. Control group 
(untransfected cells); naga group (cells transfected with Naga-Plasmid); plasmid group (cells transfected with scramble plasmid). Data are 
shown as mean ± SEM of triplicate experiments. * P-value <0.05, ** P-value <0.01 
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Discussion 
Extracellular matrix (ECM) remodeling by cancer 
cells, promote tumor growth or invasion (29). The 
ECM mostly contains glycoprotein/proteoglycan struc-
tures. glycosaminoglycan’s (GAGs) are carbohydrate 
components (as N-acetylgalactosamines) of ECM bind-
ing to protein components and form glycoproteins of 
ECM (30). Cell surface proteoglycans and pericellular 
proteoglycans like extracellular proteoglycan that 
contain GalNAc (as GAG’s) may be targets of nagalase 
(31). Many kinds of ligands on the surface of cells and 
ECM receptors that play important role in metastasis, 
migration, angiogenesis, proliferation and cell signal-
ing are composed of GAGs (32). Also, several evidences 
have shown that stiffness of ECM encourages cell 
migration, named durotaxis (33). Due to the function of 
nagalase in glycoprotein destruction, it seems nagalase 
can affect durotaxis by ECM-degradation. All issues 
mentioned above, presents the role of nagalase in 
digestion of GalNAc’s upon glycoproteins (34, 35). As 
proved, GalNAc’s were digested by ECM-degrading 
enzyme, it is possible to be done by the nagalase enzyme 
(34, 36). 
In addition, macrophage–ECM interactions in the 
tumor microenvironment have the most important 
role in macrophage polarization and function (37). 
Also, researchers have proved the role of nagalase in 
macrophage activating factor (MAF) deactivation 
through deglycosilation (20, 38). Increased serum levels 
of nagalase in patients with different types of cancer; 
particularly metastatic process has been proven in  
many studies (4, 5, 8). Furthermore, glycosylation 
modification of antibodies is important for their stability 
and efficiency as cell surface receptors (39-42). Several 
studies have mentioned glycosylation modification may 
change antibody functions as can affect other 
glycoprotein (43-45). Therefore, it can be concluded that 
any change mediated by nagalase in addition to affecting 
the performance of ligands on cell surface or ECM, can 
affect antibodies.  
Our results indicate that inhibition of nagalase 
using shRNA downregulation can be effective in 
suppression of migration and invasion in cancer cells. 
There are very limited studies that have evaluated the 
role of nagalase in ECM degradation/remodeling. 
However, they have not addresses enzymes/isoenzymes 
with similar function. Increased level of N-acetylgalacto- 
saminyl transferase was reported in the tissue of 
breast cancer patients as well as breast cancer cell 
lines (46, 47). Similarly, Taniuchi and colleague 
confirmed these findings and stated the polypeptide 
N-acetylgalactosaminyl-transferases-T3 suppression 
induces apoptosis of PDAC as pancreatic cancer cell 
line (48). The role of β-N-acetylglucosaminidase                
(β-NAG) as a hexosaminidase was proven in breast 
cancer cell lines (MDA-MB435 and MCF7) invasion by 
Ramessur  et al (49). Also, in a study conducted by Li 
et al. downregulation of N-acetylglucosaminyl transferase-
V significantly suppressed tumor progression in 
MA782 cells as mouse mammary adenocarcinoma 
(50). In addition, multiple ECM degrading/modifying 
enzymes have been identified so far, and their similar 
effects in ECM degradation have been proven. Some of 
these enzymes are proteases such as MMPs (51), 
cathepsin-L (52), heparanase (53) and others are 
hexosaminidase in which the Nagalase  is classified 
into them (54) . 
 
Conclusion  
Our findings showed that Naga downregulation by 
shRNA can be effective in migration and invasion 
potential of breast (MCF7) and ovarian (A2780) 
cancer cell lines. Although there is conflicting 
evidence in this context based on the results of the 
present study, due to the limitation on financial 
resources, it is not possible to examine other aspects 
of the nagalase function and will be investigated in 
future studies. Nevertheless, nagalase is suggested as 
a potential target for more investigation regarding 
occurrence and expansion of cancer.  
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